1,301 results on '"Bensussan, Armand"'
Search Results
2. IFNα induces CCR5 in CD4+ T cells of HIV patients causing pathogenic elevation
3. Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications
4. Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre
5. Coencapsulation of Immunosuppressive Drug with Anti-Inflammatory Molecule in Pickering Emulsions as an Innovative Therapeutic Approach for Inflammatory Dermatoses
6. The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma
7. Targeting TGF-beta activation in cutaneous T-cell lymphomas
8. “Co-encapsulation of Immunosuppressive Drug with Anti-inflammatory Molecule in Pickering Emulsions as a Novel Therapeutic Approach for Inflammatory Dermatoses”
9. PAK1-Dependent Antitumor Effect of AAC-11‒Derived Peptides on Sézary Syndrome Malignant CD4+ T Lymphocytes
10. ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells
11. CD39 is expressed by a wide range of cutaneous T‐cell lymphomas
12. The HLA-B*57:01 allele corresponds to a very large MHC haploblock likely explaining its massive effect for HIV-1 elite control
13. Microenvironment tailors nTreg structure and function
14. In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies
15. CD160
16. Targeting TGF-β Activation in Cutaneous T-Cell Lymphomas
17. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
18. CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas
19. Impact of prednisone in patients with repeated embryo implantation failures: Beneficial or deleterious?
20. Epidermal IL-33 drives inflammation in necroptosis-induced skin inflammation by recruiting TNF-producing immune cells
21. Early Elevated IFNα Identified as the Key Mediator of HIV Pathogenesis and its low level a Hallmark of Elite Controllers
22. IFNα induces CCR5 in CD4+ T-cells, causing its anti- HIV inefficiency and its subsequent pathogenic elevation, partially controlled by anti-HIV therapy
23. Engagement of CD160 Receptor by HLA-C Is a Triggering Mechanism Used by Circulating Natural Killer (NK) Cells to Mediate Cytotoxicity
24. Uterine immune profiling for increasing live birth rate: A one-to-one matched cohort study
25. Syndrome de Sézary.
26. Modulation of NK cell activation by exogenous calcium from alginate dressings in vitro
27. Abstract 710: Preclinical development of ALD2510, a Next-Gen Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors
28. Abstract 464: AAC-11 survival pathways as therapeutic target in cancer: AAC-11 leucine-zipper domain derived peptides exert potent antitumor effects and exhibit favorable stability, pharmacokinetic and toxicology profiles
29. Abstract 3644: Targeting the CD51/TGF-beta pathway: a potential innovative cancer immunotherapy in T-cell lymphomas
30. Data from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
31. Supplementary Figure 1 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
32. Supplementary Figure 4 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
33. Supplementary Material and Methods; Figure Legends from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
34. Supplementary Figure 5 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
35. Supplementary Figure 2 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
36. Supplementary Figure 3 from Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity
37. Exploring the non-lymphocytic cutaneous microenvironment in advanced cutaneous T-cell lymphomas using single-cell RNA-sequencing
38. Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3
39. Human CD100, a Novel Leukocyte Semaphorin that Promotes B-Cell Aggregation and Differentiation
40. O-103 - CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas
41. Fc receptors act as innate immune receptors during infection?
42. CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas
43. Colony Stimulating Factors 1, 2, 3 and early pregnancy steps: from bench to bedside
44. CD24hiCD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease
45. Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations
46. Biological Characterization and Differential Gene Expression Analysis of CYT-338 NK Cell Engager (NKE) Against CD38 Expressing Tumors Including Multiple Myeloma (MM)
47. CD160 receptor in CLL: Current state and future avenues
48. 1339 ALD2510: next generation Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody with promising potential for the treatment of gynecological cancers
49. CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas
50. HACE1, a Potential Tumor Suppressor Gene on 6q21, Is Not Involved in Extranodal Natural Killer/T-Cell Lymphoma Pathophysiology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.